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C1554 Meta-analysesPrognostic superiority of daytime ambulatory over
conventional blood pressure in four populations:
a meta-analysis of 7030 individuals
Tine W. Hansena,f, Masahiro Kikuyab, Lutgarde Thijsc,
Kristina Bjo¨rklund-Bodega˚rdd, Tatiana Kuznetsovac,
Takayoshi Ohkubob, Tom Richartc, Christian Torp-Pedersenf,
Lars Linde, Jørgen Jeppesenf, Hans Ibsenf, Yutaka Imaib and
Jan A. Staessenc, on behalf of the IDACO InvestigatorsObjective To investigate the multivariate-adjusted
predictive value of systolic and diastolic blood pressures on
conventional (CBP) and daytime (10–20 h) ambulatory
(ABP) measurement.
Methods We randomly recruited 7030 subjects (mean age
56.2 years; 44.8% women) from populations in Belgium,
Denmark, Japan and Sweden. We constructed the
International Database on Ambulatory blood pressure and
Cardiovascular Outcomes.
Results During follow-up (median U 9.5 years), 932
subjects died. Neither CBP nor ABP predicted total
mortality, of which 60.9% was due to noncardiovascular
causes. The incidence of fatal combined with nonfatal
cardiovascular events amounted to 863 (228 deaths, 326
strokes and 309 cardiac events). In multivariate-adjusted
continuous analyses, both CBP and ABP predicted
cardiovascular, cerebrovascular, cardiac and coronary
events. However, in fully-adjusted models, including both
CBP and ABP, CBP lost its predictive value (P >– 0.052),
whereas systolic and diastolic ABP retained their prognostic
significance (P<— 0.007) with the exception of diastolic ABP
as predictor of cardiac and coronary events (P >– 0.21). In
adjusted categorical analyses, normotension was the
referent group (CBP < 140/90 mmHg and ABP < 135/
85 mmHg). Adjusted hazard ratios for all cardiovascular
events were 1.22 [95% confidence interval (CI) U 0.96–1.53;
P U 0.09] for white-coat hypertension (>– 140/90 and
< 135/85 mmHg); 1.62 (95% CI U 1.35–1.96; P < 0.0001) foropyright © Lippincott Williams & Wilkins. Unautho
0263-6352  2007 Lippincott Williams & Wilkinsmasked hypertension (< 140/90 and >– 135/85 mmHg); and
1.80 (95% CI U 1.59–2.03; P < 0.0001) for sustained
hypertension (>– 140/90 and >– 135/85 mmHg).
Conclusions ABP is superior to CBP in predicting
cardiovascular events, but not total and noncardiovascular
mortality. Cardiovascular risk gradually increases from
normotension over white-coat and masked hypertension to
sustained hypertension. J Hypertens 25:1554–1564Q 2007
Lippincott Williams & Wilkins.
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Current guidelines define normotension and sustained
hypertension as a consistently normal or elevated blood
pressure on both conventional office and ambulatory
measurement [1,2]. White-coat hypertension is a raised
conventional blood pressure in the presence of a normal
daytime blood pressure, whereas masked hypertension is
an elevated daytime blood pressure with normal conven-
tional blood pressure [1,2]. Several prospective studies
have addressed the cardiovascular risk associated with
white-coat [3–12] and masked hypertension [9,11–13].
Most studies involved hypertensive patients [3–7],including [3,6] or excluding [4,5,7] a normotensive con-
trol group. Fewer reports were population-based [9,11–
13] or pooled hypertensive patients with randomly
recruited subjects [10]. The interpretation of previous
studies on white-coat [3–12] and masked [9,11–13] hy-
pertension is difficult, due to divergent thresholds for
ambulatory hypertension, and because, in some studies,
most patients were followed up when they were on
antihypertensive drug treatment [4,7], and/or because
of the relatively low incidence of events [5,7,8], short
duration of follow-up [3,5–7] or restriction of follow-up to
mortality [12].rized reproduction of this article is prohibited.
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studies with the goal to investigate the relation between
fatal and nonfatal outcomes and the ambulatory and
conventional blood pressures based on long-term fol-
low-up and a large number of events, while adjusting
for cardiovascular risk factors [14,15]. In the present
study, we assessed risk associated with the conventional
and ambulatory blood pressures analysed as continuous
exposure variables. We also reported estimates of risk
associated with white-coat and masked hypertension,
relative to normotension and sustained hypertension.
Methods
Study population
We constructed the International Database on Ambulatory
blood pressure monitoring in relation to Cardiovascular
Outcomes (IDACO) [14,15]. Studies were eligible for
inclusion, if they involved a random population sample,
if information on the conventional and ambulatory blood
pressures and cardiovascular risk factors were available at
baseline, and if the subsequent follow-up included fatal
and nonfatal outcomes. An electronic search of the English
literature, using ‘ambulatory blood pressure monitoring’
and ‘population’ as search terms identified eleven studies
[11–13,16–23]. Seven were excluded because follow-up
was still ongoing [17,19–23] or because follow-up did not
include nonfatal events [12].
For the current analysis, we considered 2311 residents
from Copenhagen, Denmark [11], 2542 subjects
recruited from Noorderkempen, Belgium [18], 1535
inhabitants of Ohasama, Japan [16], and 1221 men from
the population of Uppsala, Sweden [13]. Thus, on 30
April 2006, the number of subjects available for analysis
totalled 7609. All studies included randomly selected
population samples and the participation rates were
70.2% in Copenhagen [11], 70.0% in Belgium [18],
77.1% in Ohasama [16] and 72.6% in Uppsala [13]. All
studies contributing to the IDACO database received
ethical approval and have been described in detail
[11,13,16,18]. All participants provided their informed
written consent. Of the 7609 subjects, 579 were excluded
because their conventional (n¼ 220) or daytime ambu-
latory blood pressure (n¼ 79) was not measured, because
their daytime ambulatory blood pressure was the average
of fewer than ten readings (n¼ 53), or because they were
younger than 18 years at enrolment (n¼ 227). Thus, the
number of subjects included in the present analyses
totalled 7030.
Conventional and ambulatory blood pressure
measurement
Experienced observers measured the conventional blood
pressure with a standard mercury sphygmomanometer
[11,13,18] or a validated [24] auscultatory device (USM-
700F; UEDA Electronic Works, Tokyo, Japan) [16], using
the appropriate cuff size, after the subjects had rested for atopyright © Lippincott Williams & Wilkins. Unauthleast 2 min in the sitting [11,16,18] or supine [13] position.
The conventional blood pressure was the average of two
consecutive readings obtained either at the subjects’
homes [18] or at an examination centre [11,13,16].
We programmed portable blood pressure monitors to
obtain daytime readings at intervals ranging from
15 min [11] to 30 min [16]. The devices implemented
an auscultatory algorithm (Accutracker II; Suntech
Medical Instruments Inc., Morrisville, North Carolina,
USA) [25] in Uppsala [13] or an oscillometric technique
(SpaceLabs 90202 and 90207; SpaceLabs Inc., Redmond,
Washington, USA) [26,27] in Noorderkempen [18]. The
Takeda TM-2421 recorders (A&D, Tokyo, Japan) [28]
and the ABPM-630 devices (Nippon Colin, Komaki,
Japan) [29], used in Copenhagen [11] and Ohasama
[16], respectively, implemented both techniques, but
only the oscillometric readings were analyzed.
To achieve a high degree of standardization, the same
SAS macro (SAS software, version 9.1; SAS Institute,
Cary, North Carolina, USA) processed all individual
recordings, which stayed either unedited [11,13,18] or
were only minimally edited [16], according to previously
published criteria [30]. We calculated the averaged day-
time blood pressure weighted for the time interval
between consecutive readings. Accounting for the pat-
tern of the daily activities of the study participants, we
defined daytime as the interval ranging from 1000 h to
2000 h in Europeans [11,13,18], and from 0800 h to 1800 h
in Japanese [16]. Pulse pressure was the difference
between the systolic and diastolic blood pressure. Mean
arterial pressure was diastolic blood pressure plus one-
third of pulse pressure.
In line with current guidelines for the diagnosis and
management of hypertension [1,2], we defined conven-
tional hypertension as a blood pressure equal to or
exceeding 140 mmHg systolic or 90 mmHg diastolic.
The corresponding thresholds for ambulatory hyperten-
sion were 135 mmHg systolic and 85 mmHg diastolic.
In line with suggestions by Verdecchia et al. [31], we
also defined ambulatory hypertension, using 130 and
80 mmHg as systolic and diastolic cut-off limits. Patients
on antihypertensive drug treatment were classified
according to their treated blood pressure. Normotension
and sustained hypertension were a consistently normal or
elevated blood pressure on both conventional and ambu-
latory measurement [1,2]. White-coat hypertension was a
raised conventional blood pressure in the presence of a
normal daytime blood pressure [1,2]. Masked hyperten-
sion was an elevated ambulatory blood pressure with
normal conventional blood pressure [1,2].
Other measurements
In all cohorts, a questionnaire was used to obtain detailed
information on each subject’s medical history, intake oforized reproduction of this article is prohibited.
C1556 Journal of Hypertension 2007, Vol 25 No 8medications, and lifestyle. We defined smoking and
drinking as the current use of tobacco and alcohol. Body
mass index was body weight in kilograms divided by
height in meters squared (kg/m2). Previous cardiovascular
disease included cardiac disorders, stroke, transient
ischemic attack, and peripheral vascular disease. Total
serum cholesterol and blood glucose were determined by
automated enzymatic methods on venous blood samples.
Diabetes mellitus was a self-reported diagnosis, a fasting
or random blood glucose level of at least 7.0 mmol/l
(126 mg/dl) or 11.1 mmol/l (200 mg/dl), respectively, or
use of antidiabetic drugs [32].
Ascertainment of events
We ascertained vital status and the incidence of fatal and
nonfatal diseases from the appropriate sources in each
country, as previously described in detail [11,13,33,34].
Fatal and nonfatal stroke did not include transient
ischemic attacks. Coronary events encompassed death
from ischemic heart disease, sudden death, nonfatal
myocardial infarction, and surgical and transluminal cor-
onary revascularization. Cardiac events comprised coron-
ary endpoints and fatal and nonfatal heart failure. In the
Danish [11] and Swedish [13] cohorts, the diagnosis of
heart failure required hospitalization. In the Japanese
[16,33] and Belgian [18,34] cohorts, heart failure was
either a clinical diagnosis or the diagnosis on the death
certificate but, in all cases, validated against hospital
records or the records held by general practitioners.
The composite cardiovascular endpoint included all
aforementioned endpoints plus cardiovascular mortality.
In all outcome analyses, we only considered the first
event within each category.
Statistical analysis
For database management and statistical analysis, we
used SAS software, version 9.1 (SAS Institute). For com-
parison of means and proportions, we applied the stan-
dard normal z-test for large samples and the chi-squared
test, respectively. We first plotted the incidence of car-
diovascular events according to the cross classification of
subjects by conventional and ambulatory blood pressure
measurement, using Cox models standardized to the sex
distribution and mean age of the whole study population.
We ascertained that the proportional hazard assumption
underlying Cox regression was fulfilled by testing the
interaction between follow-up time and blood pressure
categories. Next, we modelled the multivariate-adjusted
risk associated with the conventional and ambulatory
blood pressures treated both as continuous and as categ-
orical variables. In these Cox regression models, we
adjusted for cohort, sex, age, body mass index, serum
cholesterol, smoking and drinking, history of cardiovas-
cular disease, diabetes mellitus, and antihypertensive
drug treatment. We adjusted for cohort by introducing
three design variables in the Cox models. We additionally
adjusted the Cox models relating outcome to pulseopyright © Lippincott Williams & Wilkins. Unauthopressure for mean arterial pressure [35]. For the categ-
orical analyses, we presented hazard ratios as floating
absolute risks and calculated their standard errors as
described by Easton et al. [36]. This approach allows
the calculation of a 95% confidence interval (CI) for the
relative risk in the referent group. We evaluated differ-
ences between hazard ratios, using the test statement
in the Cox regression procedure, as implemented in
the SAS package. P< 0.05 (two-tailed) was considered
statistically significant.
Results
Baseline characteristics of the participants
The 7030 subjects included 3148 (44.8%) women and
1520 patients (21.8%) on antihypertensive drug treat-
ment. MeanSD values were 56.2 14.4 years for age,
131.8 19.6 mmHg and 79.4 11.3 mmHg for systolic
and diastolic blood pressure on conventional measure-
ment, and 131.8 14.9 mmHg and 78.5 9.1 mmHg for
systolic and diastolic blood pressure on daytime monitor-
ing. Of the participants, 3473 (49.4%) had normotension,
743 (10.6%) had white-coat hypertension, 1024 (14.6%)
had masked hypertension, and 1790 (25.4%) had sus-
tained hypertension. Table 1 shows the baseline charac-
teristics of these four groups. Between-group differences
were significant for all variables (P< 0.0001). Across
cohorts, the prevalence of white-coat hypertension was
lowest in Copenhagen and highest in Uppsala (6.7 versus
17.0%), whereas the opposite was true for the prevalence
of masked hypertension (20.1 versus 11.3%).
Exploratory analyses
During follow-up (median¼ 9.5 years; 5th to 95th per-
centile interval¼ 2.7–14.0 years), 64 958 person-years
accrued. Figure 1 shows the incidence of cardiovascular
events in the four blood pressure groups with rates
standardized to the sex distribution and mean age of
the whole study population. The incidence of cardiovas-
cular events increased from normotension over white-
coat and masked hypertension to sustained hypertension
(P for trend < 0.0001). The number of events and crude
incidence rates expressed in percentage are shown in
Table 2 for mortality and in Table 3 for fatal and nonfatal
cardiovascular events combined. Cardiac events con-
sisted of 147 fatal and 321 nonfatal events, including
47 fatal and 168 nonfatal cases of acute myocardial
infarction, 79 sudden deaths, 21 fatal and 127 nonfatal
cases of heart failure, and 26 cases of surgical and percu-
taneous coronary revascularization. Most revasculari-
zation procedures occurred in Belgium (n¼ 20) and a
few others occurred in Denmark (n¼ 6).
Adjusted continuous analyses
The multivariate-adjusted hazard ratios (95% CI) associ-
ated with each 10-mmHg increase in systolic blood
pressure or pulse pressure or each 5-mmHg increase in
diastolic blood pressure are shown in Table 2 forrized reproduction of this article is prohibited.
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Table 1 Baseline characteristics of participants by cross-classification of conventional and daytime blood pressures
Characteristic Normotension (n¼3473) White-coat HT (n¼743) Masked HT (n¼1024) Sustained HT (n¼1790)
Anthropometrics
Women (n) 1909 (55.0) 300 (40.4) 406 (39.7) 533 (29.8)
Age (years) 50.914.7 62.312.0 56.513.0 63.610.6
Body mass index (kg/m2) 24.53.7 26.04.4 25.83.9 27.04.1
Conventional blood pressure (mmHg)
Systolic 118.910.7 148.012.8 125.69.2 153.815.1
Diastolic 73.18.1 85.99.5 77.57.6 90.09.9
Pulse pressure 45.79.9 62.215.7 48.110.3 63.715.6
Daytime blood pressure (mmHg)
Daytime systolic 121.47.8 126.36.5 141.28.3 148.711.8
Daytime diastolic 73.55.9 74.96.0 84.07.3 86.58.7
Pulse pressure 48.06.4 51.46.9 57.69.6 62.411.1
Risk factors
Antihypertensive treatment (n) 421 (12.1) 290 (39.0) 191 (18.7) 618 (34.5)
Current smokers (n) 1093 (31.6) 142 (19.4) 391 (38.4) 507 (28.5)
Current drinkers (n) 1425 (43.4) 316 (51.2) 622 (65.2) 1136 (73.9)
Serum cholesterol (mmol/l) 5.471.09 5.861.15 5.801.11 5.961.13
History of cardiovascular disease (n) 213 (6.1) 97 (13.0) 84 (8.2) 199 (11.1)
Diabetes mellitus (n) 157 (4.5) 67 (9.0) 83 (8.1) 184 (10.3)
Data are meanSD or number of subjects (%). HT, Hypertension (for conventional and ambulatory thresholds, see Methods). All between-group differences were
significant (P0.0001).mortality and in Table 3 for fatal combined with nonfatal
cardiovascular events. We adjusted all analyses for cohort,
sex, age, body mass index, serum cholesterol, smoking
and drinking, history of cardiovascular disease, diabetes
mellitus, and antihypertensive drug treatment. The
analyses involving pulse pressure were also adjusted
for mean arterial pressure [35]. Fully-adjusted models
included blood pressure on conventional as well as day-
time ambulatory measurement.
In adjusted and fully-adjusted models, the three blood
pressure components on daytime ambulatory measure-
ment, but not on conventional measurement, were sig-
nificant predictors of cardiovascular mortality, but not of
total mortality. Systolic and diastolic blood pressure and
pulse pressure on conventional as well as ambulatory
measurement did not predict noncardiovascular mortalityopyright © Lippincott Williams & Wilkins. Unauth
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Incidence of cardiovascular events according to the cross classification of
normotension; WHT, white-coat hypertension; MH, masked hypertension; H
(130/80 mmHg) or (b) higher (135/85 mmHg) cut-off limits for daytime
distribution and mean age in the whole study population. The P-values arein adjusted (P 0.44) or fully adjusted (P 0.49) models
(Table 2). This explains the weak association of total
mortality (55.6% due to noncardiovascular causes) with
the daytime ambulatory blood pressure in adjusted
(0.014P 0.30) and fully-adjusted (P 0.14) models
(Table 2).
Figure 2 shows the 10-year absolute risk of cardiovascular
events in continuous analyses adjusted for cohort and the
aforementioned risk factors. In fully-adjusted models, the
daytime blood pressure remained a significant predictor
for all cardiovascular events over and beyond the con-
ventional blood pressure (Table 3 and Fig. 2). This was
also the case for cause-specific cardiovascular endpoints
with the exception of the daytime diastolic blood
pressure as predictor of cardiac events (hazard ratio,
1.03; P¼ 0.45) and coronary heart disease, including ororized reproduction of this article is prohibited.
years)
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subjects by conventional and daytime ambulatory blood pressure. NT,
T, sustained hypertension. The analyses were based on (a) lower
ambulatory hypertension. Incidence was standardized to the sex
for trend across the blood pressure groups.
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Table 2 Multivariate-adjusted hazard ratios for mortality
Label Total Noncardiovascular Cardiovascular
Number of deaths, n (%) 932 (13.3) 524 (7.4) 364 (5.2)
Conventional blood pressure
Systolic Adjusted 1.05 (1.00–1.09)M 1.01 (0.95–1.07) 1.10 (1.03–1.17)
Fully adjusted 1.03 (0.98–1.08) 1.02 (0.95–1.09) 1.03 (0.96–1.11)
Diastolic Adjusted 1.01 (0.98–1.05) 0.99 (0.94–1.04) 1.05 (0.99–1.11)
Fully adjusted 1.00 (0.96–1.05) 1.00 (0.95–1.06) 1.00 (0.94–1.07)
Pulse pressure Adjusted 1.05 (0.99–1.12) 1.03 (0.95–1.12) 1.07 (0.98–1.18)
Fully adjusted 1.03 (0.97–1.10) 1.03 (0.94–1.13) 1.03 (0.93–1.13)
Daytime blood pressure
Systolic Adjusted 1.07 (1.01–1.12)M 0.99 (0.92–1.06) 1.18 (1.09–1.27)z
Fully adjusted 1.05 (0.99–1.11) 0.99 (0.90–1.07) 1.16 (1.05–1.27)y
Diastolic Adjusted 1.02 (0.98–1.07) 0.99 (0.94–1.04) 1.11 (1.04–1.18)y
Fully adjusted 1.02 (0.96–1.05) 0.98 (0.91–1.05) 1.11 (1.03–1.20)y
Pulse pressure Adjusted 1.08 (0.99–1.17) 1.04 (0.93–1.17) 1.09 (0.96–1.23)
Fully adjusted 1.06 (0.97–1.16) 1.02 (0.90–1.16) 1.06 (0.92–1.21)
The cause of death was unknown in 44 cases. Hazard ratios (95% confidence interval) are for the risk associated with 10-mmHg increases in systolic blood pressure and
pulse pressure or 5-mmHg increases in diastolic blood pressure. All hazard ratios were adjusted for cohort, sex, age, body mass index, serum cholesterol, smoking and
drinking, history of cardiovascular disease, diabetes mellitus, and antihypertensive drug treatment. Hazard ratios for pulse pressure were additionally adjusted for mean
arterial pressure. Models including both conventional as well as daytime blood pressure are labelled as fully adjusted. Significance of the hazard ratios: MP<0.05,
yP<0.01, zP<0.0001.excluding the 26 incident cases of coronary revasculari-
zation (hazard ratios  1.05; P 0.21). By contrast, in
fully-adjusted models, the conventional blood pressure
was not predictive of fatal combined with nonfatal out-
comes, over and beyond the ambulatory daytime blood
pressure.
Adjusted categorical analyses
Figure 3 shows the hazard ratios (95% CI) for all com-
bined cardiovascular events according to the cross-classi-
fication of conventional and daytime ambulatory blood
pressure. Cardiovascular risk increased across the hyper-
tensive groups with the highest risk in the patients with
sustained hypertension (P-value for trend < 0.0001).
These results were consistent in analyses based on the
higher ( 135/85 mmHg) and lower ( 130/80 mmHg)
[31] cut-off limits for daytime ambulatory hypertension.opyright © Lippincott Williams & Wilkins. Unautho
Table 3 Multivariate-adjusted hazard ratios for fatal and nonfatal even
Label All events Strok
Number of events, n (%) 863 (12.3) 397 (5.7)
Conventional blood pressure
Systolic Adjusted 1.12 (1.08–1.17)z 1.13 (1.07–
Fully adjusted 1.05 (1.00–1.10) 1.05 (0.98–
Diastolic Adjusted 1.07 (1.03–1.11)z 1.09 (1.03–
Fully adjusted 1.03 (0.99–1.07) 1.02 (0.96–
Pulse pressure Adjusted 1.08 (1.01–1.15)M 1.06 (0.97–
Fully adjusted 1.02 (0.96–1.09) 1.01 (0.92–
Daytime blood pressure
Systolic Adjusted 1.21 (1.15–1.27)z 1.25 (1.16–
Fully adjusted 1.17 (1.10–1.24)z 1.21 (1.12–
Diastolic Adjusted 1.11 (1.07–1.15)z 1.17 (1.10–
Fully adjusted 1.09 (1.04–1.14)z 1.15 (1.08–
Pulse pressure Adjusted 1.14 (1.05–1.23)y 1.06 (0.94–
Fully adjusted 1.11 (1.02–1.21)M 1.03 (0.90–
CHDþ/CHD– indicate coronary heart disease including/excluding coronary bypass s
confidence interval) are for the risk associated with 10-mmHg increases in systolic blood
hazard ratios were adjusted for cohort, sex, age, body mass index, serum cholestero
antihypertensive drug treatment. Hazard ratios for pulse pressure were additionally ad
daytime blood pressure are labelled as fully adjusted. Significance of the hazard ratioCompared to normotension, white-coat hypertensive
patients had a slightly increased risk, but none of the
hazard ratios reached significance (0.63P 0.09;
Fig. 3). Using 135/85 mmHg as the cut-off limit, white-
coat hypertensive patients had higher daytime blood
pressures than the normotensive reference group. The
differences averaged 4.9 mmHg systolic and 1.4 mmHg
diastolic (no P-values calculated because the classifi-
cation rested on blood pressure). After additional adjust-
ment for the daytime systolic blood pressure, the hazard
ratios associated with white-coat hypertension were 1.16
(95% CI¼ 0.91–1.47; P¼ 0.23) for all cardiovascular
events, 1.03 (95% CI¼ 0.72–1.49; P¼ 0.87) for stroke,
and 1.22 (95% CI¼ 0.87–1.69; P¼ 0.24) for cardiac
events. The hazard ratios, relative to normotension, were
similar for masked hypertension and sustained hyperten-
sion (P 0.14) with the exception of the hazard ratio forrized reproduction of this article is prohibited.
ts combined
e Cardiac CHDþ CHD
468 (6.7) 353 (5.0) 333 (4.7)
1.20)z 1.12 (1.06–1.19)z 1.10 (1.03–1.18)y 1.11 (1.04–1.19)y
1.12) 1.06 (0.99–1.13) 1.02 (0.94–1.11) 1.03 (0.95–1.12)
1.14)y 1.08 (1.02–1.13)M 1.09 (1.03–1.15)z 1.09 (1.02–1.16)y
1.08) 1.06 (0.99–1.13) 1.05 (0.98–1.13) 1.06 (0.98–1.14)
1.16)y 1.10 (1.01–1.19)M 1.01 (0.92–1.12) 1.02 (0.92–1.13)
1.11) 1.02 (0.93–1.12) 0.94 (0.85–1.05) 0.95 (0.85–1.06)
1.34)z 1.18 (1.10–1.26)z 1.19 (1.10–1.29)z 1.20 (1.11–1.30)z
1.32)z 1.13 (1.04–1.23)z 1.17 (1.07–1.29)z 1.18 (1.07–1.30)y
1.23)z 1.07 (1.01–1.13)M 1.09 (1.03–1.17)y 1.09 (1.02–1.17)M
1.23)z 1.03 (0.96–1.10) 1.06 (0.98–1.15) 1.05 (0.96–1.15)
1.20) 1.22 (1.10–1.35)z 1.16 (1.02–1.31)M 1.17 (1.03–1.33)M
1.33) 1.19 (1.06–1.33)y 1.17 (1.02–1.33)M 1.18 (1.03–1.35)M
urgery and percutaneous transluminal coronary angioplasty. Hazard ratios (95%
pressure and pulse pressure or 5-mmHg increases in diastolic blood pressure. All
l, smoking and drinking, history of cardiovascular disease, diabetes mellitus, and
justed for mean arterial pressure. Models including both conventional as well as
s: MP<0.05, yP<0.01, zP<0.0001.
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Fig. 2
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Absolute 10-year risk of a cardiovascular event in relation to the conventional and daytime ambulatory blood pressure. ABP, Ambulatory daytime
blood pressure; CBP, conventional blood pressure. Risk estimates are for (a) systolic blood pressure and (b) diastolic blood pressure and were
adjusted for cohort, sex, age, body mass index, serum cholesterol, smoking and drinking, history of cardiovascular disease, diabetes mellitus, and
antihypertensive drug treatment. P-values are for the independent contributions of ABP and CBP to risk.all cardiovascular events based on the lower definition
( 130/80 mmHg) of ambulatory hypertension (1.44
versus 1.77; P¼ 0.036; Fig. 3).
With all fatal and nonfatal cardiovascular events as out-
come, we performed sensitivity analyses (Table 4), which
we adjusted as before and which were based on the
higher cut-off limit for ambulatory hypertension
( 135/85 mmHg). The results in women and men, at
younger (< 60 years) and older ( 60 years) age, and in
subjects taking or not taking antihypertensive drugs at
baseline, were consistent (P-values for interaction 0.18)
and confirmed the observations in all subjects (Table 3
and Fig. 2). Moreover, analyses from which we excluded
subjects with previous cardiovascular disease or from
which we excluded one cohort at a time were also con-
firmatory (Table 4). Thus, previous cardiovascular dis-
ease or one particular cohort did not drive our main
results. Similarly, when we excluded incident cases of
surgical and percutaneous coronary revascularization, our
conclusions also remained unchanged (Table 4).
By censoring the adjusted Cox models for all cardiovas-
cular events at 6, 9 and 12 years [10], we furthermore
explored whether the risk of white-coat hypertension,
compared to normotension, changed with longer follow-
up. For the higher threshold of ambulatory hypertension
( 135/85 mmHg), the hazard ratios were 1.08 (95%
CI¼ 0.61–1.88; P¼ 0.79), 1.20 (95% CI¼ 0.86–1.69;
P¼ 0.29) and 1.30 (95% CI¼ 1.01–1.68; P¼ 0.043), when
censoring at 6, 9 and 12 years. The corresponding hazard
ratios for white-coat hypertension compared to sustainedopyright © Lippincott Williams & Wilkins. Unauthhypertension were 0.64 (95% CI¼ 0.37–1.12; P¼ 0.11),
0.65 (95% CI¼ 0.46–0.91; P¼ 0.013) and 0.73 (95%
CI¼ 0.57–0.94; P¼ 0.014), respectively. For the entire
follow-up period (without censoring), the hazard ratio
for white-coat hypertension compared to sustained
hypertension was 0.68 (95% CI¼ 0.52–0.87; P¼ 0.003).
Discussion
Our current meta-analysis of individual subject data
included over 7000 people randomly recruited from four
populations and covered approximately 10 years of fol-
low-up with more than 800 new cardiovascular endpoints.
The key finding was that ambulatory blood pressure
monitoring was by far superior to conventional blood
pressure measurement in the prediction of cardiovascular
events and risk stratification. These results rested prim-
arily on continuous analyses unbiased by the application
of arbitrary blood pressure thresholds. Furthermore,
categorical analyses confirmed the superiority of ambu-
latory monitoring over conventional blood pressure and
demonstrated that the risks conferred by white-coat
hypertension and masked hypertension were intermedi-
ate to those associated with normotension and sustained
hypertension. Finally, we noticed that, over a prolonged
period of follow-up, the risk of white-coat hypertension
remained significantly less than that of sustained hyper-
tension.
In 1983, Perloff et al. [37] reported for the first time that
the portion of the daytime ambulatory blood pressure,
which was not already explained by systolic or diastolic
clinic blood pressure, could discriminate high-risk fromorized reproduction of this article is prohibited.
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Hazard ratios for cardiovascular events according to the cross-classification of conventional and daytime ambulatory blood pressure. NT,
normotension; WC-HT, white-coat hypertension; M-HT, masked hypertension; S-HT, sustained hypertension. NT is the reference group (	P<0.01;
yP<0.001). The analyses were based on (a) lower (130/80 mmHg) or (b) higher (135/85 mmHg) cut-off limits for ambulatory hypertension and
were adjusted for cohort, sex, age, body mass index, serum cholesterol, smoking and drinking, history of cardiovascular disease, diabetes mellitus,
and antihypertensive drug treatment. Squares are proportional to the number of events per group. Horizontal lines denote the 95% confidence
interval.low-risk hypertensive patients. These results obtained by
life-table analysis from semi-automated recordings in
1076 hypertensive patients were later confirmed by
Cox regression in a subgroup of 761 patients, who were
all untreated at baseline [38]. Subsequently, severalopyright © Lippincott Williams & Wilkins. Unauthostudies replicated Perloff’s seminal observations in
hypertensive patients [3–7,39–42] or population cohorts
[9,11–13]. On balance, these studies confirmed that
ambulatory blood pressure monitoring provided better
prognostic accuracy than conventional blood pressurerized reproduction of this article is prohibited.
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Table 4 Hazard ratios for cardiovascular event in subgroups with daytime blood pressure threshold set at 135/85 mmHg
Stratification At risk (n) Events (n) White-coat HT Masked HT Sustained HT
Baseline characteristic
Women 3148 211 0.90 (0.53–1.53) 1.85 (1.23–2.77)z 1.74 (1.22–2.49)z
Men 3882 652 1.37 (0.99–1.89) 1.53 (1.13–2.07)z 1.83 (1.43–2.33)z
<60 years 3555 118 0.68 (0.28–1.67) 1.79 (1.16–2.76)z 2.20 (1.48–3.29)z
60 years 3475 745 1.27 (0.95–1.70) 1.57 (1.20–2.06)z 1.74 (1.40–2.17)z
Untreated 5510 489 1.25 (0.86–1.82) 1.58 (1.17–2.12)z 1.91 (1.48–2.45)z
Treated 1520 374 1.15 (0.76–1.75) 1.69 (1.12–2.57)y 1.65 (1.19–2.30)z
No history of CVD 6437 659 1.19 (0.91–1.57) 1.72 (1.40–2.12)z 1.90 (1.65–2.19)z
History of CVD 593 204 1.23 (0.74–2.05) 1.34 (0.79–2.28) 1.55 (1.04–2.30)M
Excluded cohort
Copenhagen 4735 595 1.26 (0.91–1.74) 1.64 (1.18–2.27)z 1.87 (1.43–2.44)z
Noorderkempen 4755 746 1.18 (0.86–1.63) 1.64 (1.26–2.13)z 1.68 (1.34–2.12)z
Ohasama 5711 712 1.27 (0.93–1.74) 1.56 (1.18–2.07)z 1.82 (1.45–2.29)z
Uppsala 5896 536 1.14 (0.82–1.58) 1.63 (1.24–2.12)z 1.86 (1.47–2.35)z
Incident CABG and PTCA
Included 7030 863 1.23 (0.93–1.63) 1.67 (1.31–2.13)z 1.83 (1.48–2.25)z
Excluded 7030 843 1.23 (0.92–1.63) 1.68 (1.31–2.15)z 1.83 (1.49–2.26)z
HT, Hypertension; CVD, cardiovascular disease; CABG, coronary artery bypass surgery; PTCA, percutaneous transluminal coronary angioplasty. The hazard ratios (95%
confidence interval) express the risk versus normotension and are adjusted, as appropriate, for cohort, sex, age, body mass index, serum cholesterol, smoking and drinking,
history of cardiovascular disease, diabetes mellitus, and antihypertensive drug treatment. Significance of the hazard ratios: MP<0.05, yP<0.01, zP<0.001.measurement. However, many studies [3–8], although
outcome-driven, were difficult to interpret because blood
pressure was not analyzed as a continuous variable [3–7],
because some studies did not include a normotensive
control group [4,5,7], or because investigators did not
subdivide the normotensive controls into those with
normal or elevated ambulatory blood pressure [3,6,8].
The current literature illustrates that expert opinion over
the prognostic significance of white-coat hypertension
remains widely divided [3–12]. For example, an early
study by Verdecchia et al. [3] included 1187 subjects with
essential hypertension and 205 healthy normotensive
control subjects, who all underwent baseline off-therapy
24-h ambulatory blood pressure monitoring. In the hyper-
tensive patients, the prevalence of white-coat hyperten-
sion, defined as an average daytime blood pressure lower
than 131/86 mmHg in women and 136/87 mmHg in men,
was 19.2%. After adjustment for traditional markers of
cardiovascular risk, the incidence of morbidity over a
mean follow-up of 3.2 years did not differ between the
normotensive subjects and the white-coat hypertensive
group (P¼ 0.83) [3]. Among 2051 subjects recruited
from a general Italian population [12], the PAMELA
(Pressione Arteriose Monitorate e Loro Associazione)
investigators found a significant sex and age-adjusted
increasing trend in the risk of cardiovascular mortality
from normotension over white-coat hypertension and
masked hypertension, to sustained hypertension. They
suggested that the risk associated with white-coat hyper-
tension and masked hypertension is not prognostically
innocent [12]. However, the adjusted risk conferred by
white-coat and masked hypertension did not significantly
differ from that associated with normotension [12]. In the
PAMELA publication, the threshold for ambulatory
hypertension was a 24-h blood pressure of 125 mmHg
systolic or 79 mmHg diastolic [12]. A recently publishedopyright © Lippincott Williams & Wilkins. Unauthmeta-analysis [10] included three cohorts of hyperten-
sive patients and one population sample. After 6 years
of follow-up, patients with white-coat hypertension
experienced a substantial increase in the incidence of
stroke so that, by the ninth year of follow-up, they had
attained the same stroke rate as patients with sustained
hypertension [10]. However, over the whole follow-up,
the multivariate-adjusted hazard ratio for stroke for
white-coat hypertension compared to normotension
(1.14; 95% CI¼ 0.61–2.16; P¼ 0.66) was not significant
[10]. In our current analyses, the risk of stroke associated
with white-coat hypertension versus normotension did
not increase with the duration of follow-up.
The counterpart of white-coat hypertension is masked
hypertension, a disorder characterized by a normal con-
ventional blood pressure confirmed on repeated clinic
visits, and an elevated daytime ambulatory blood pres-
sure [43]. Three studies [9,11,13] defined masked hyper-
tension based on an awake or daytime blood pressure of at
least 135 mmHg systolic or 85 mmHg diastolic. Although
the adjusted hazard ratio associated with masked hyper-
tension was not significant [11] or not formally compared
with that of sustained hypertension [9,11,13], the three
reports concluded that masked and sustained hyperten-
sion conferred similar cardiovascular risk. Based on an at
least ten-fold larger number of composite cardiovascular
endpoints, we found that, with proper adjustments
applied, the risk of masked hypertension and sustained
hypertension was of the same order of magnitude. The
only exception was the lower risk of the composite
cardiovascular endpoint in masked compared with sus-
tained hypertension (hazard ratio¼ 1.44 versus 1.77),
when we applied levels of 130 mmHg systolic and
80 mmHg diastolic as thresholds for the daytime ambu-
latory blood pressure. Fewer events and a lack of
statistical power probably explain why at the lowerorized reproduction of this article is prohibited.
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cardiac events did not significantly differ between
masked and sustained hypertension. In adolescents,
masked hypertension is a forerunner of sustained hyper-
tension and is also associated with increased left ventri-
cular mass, and therefore warrants follow-up [44].
In the current meta-analysis, we pre-emptively opted not
to combine hypertensive patients and subjects randomly
recruited from the general population [14]. We con-
sidered that, in hypertensive patients, blood pressure-
lowering treatment might be a confounder with too large
an impact to adjust for [14]. Indeed, in the older patients
with isolated systolic hypertension randomized to
placebo (n¼ 393) in the Systolic Hypertension in Europe
(Syst-Eur) trial [41], the 24-h, daytime (1000 h to 2000 h)
and night-time (0000 h to 0600 h) systolic blood pressures
all predicted the incidence of cardiovascular compli-
cations, even after further adjustment for conventional
blood pressure. By contrast, in the active treatment group
(n¼ 415), systolic blood pressure at entry did not signifi-
cantly predict cardiovascular endpoints, regardless of
the technique of blood pressure measurement [41]. In
our current meta-analysis, only one-fifth of the subjects
were on antihypertensive drug treatment at baseline.
The sensitivity analysis in untreated subjects substan-
tiated our overall conclusions and exemplified that anti-
hypertensive drug treatment at baseline was not a major
confounder. In addition, the generalizability of popu-
lation-based results is obviously larger than those emer-
ging from selected cohorts of hypertensive patients.
Furthermore, in contrast to other studies [12,39] relating
cardiovascular outcomes to conventional and ambulatory
blood pressure measurements, we chose to analyze
both fatal and nonfatal outcomes. The introduction of
stroke units and the wide availability of invasive coronary
care and thrombolysis recently reduced the case-fatality
rate of most cardiovascular complications of hyper-
tension. Not accounting for nonfatal events therefore
limits the generalizability of some previous reports
[12,33,39].
Current guidelines for the management of hypertension
move away from the concept of blood pressure as an
isolated risk factor and increasingly introduce the concept
of the management of global cardiovascular risk [45].
From this point of view, our current findings have
implications for clinical practice. The prevalence of
white-coat hypertension, as evaluated by either ambu-
latory monitoring [11,12] or blood pressure self-measure-
ment [46,47], varies from 11.5% [11] to 17.5% [12] in the
general population, and from 13.3% [46] to 43.0% [47]
among hypertensive patients. Hypertension and associ-
ated risk factors are age dependent. Any man normoten-
sive at 50 years has a probability of over 90% to become
hypertensive during the remainder of his lifetime [48].
The aging of populations is a worldwide phenomenon,opyright © Lippincott Williams & Wilkins. Unauthowhich is putting increasing demands on limited health-
care resources. Superior risk stratification is a way of
objectively informing treatment decisions and rationally
distributing medical care. A 6-month clinical trial has
already proved that optimizing antihypertensive drug
treatment on the basis of ambulatory monitoring is feas-
ible and cost-effective [49]. Our present findings there-
fore suggest that ambulatory blood pressure monitoring
should become routine in the risk stratification of patients
with hypertension.
Our study must be interpreted within the context of its
potential limitations. First, our present analysis rested
only on four population-based cohorts and might not be
representative for non-European or non-Japanese sub-
jects. Second, anthropometric characteristics differed
between cohorts. Third, most participants had their
conventional blood pressure measured while seated at
an examination centre. By contrast, the conventional
blood pressure was measured in the supine position in
Uppsala [13] and at home in Noorderkempen [18,34].
Due to regression to the mean, the most recent consensus
[2] states that a diagnosis of white-coat hypertension
requires measurement of a conventional blood pressure
of 140 mmHg systolic or 90 mmHg diastolic or higher on
at least three occasions. Furthermore, ambulatory blood
pressure monitoring was not standardized in terms of
device type and intervals between successive readings.
On the other hand, using a single SAS macro ensured that
daytime was always defined in the same fashion, using
short fixed clock-time intervals [50], and that the time-
weighted means were calculated identically across
cohorts. The inclusion of cases of surgical and percuta-
neous coronary revascularization among the coronary and
cardiovascular events might have limited the general-
izability of the results because these procedures are
subject to considerable regional variation in practice.
However, our analyses only included 26 such cases and
their exclusion confirmed our results for coronary heart
disease, as well as all cardiovascular events. Finally, we
did not adjust for antihypertensive drug treatment as a
time-dependent covariate. However, the proportion of
our patients on antihypertensive treatment at baseline
was only 21.6%. During the course of follow-up, the
proportion of treated patients, giving the poor rates of
treatment in the general population [51] and the poor
persistence of treatment in some clinical studies [52],
must have been considerably lower than in cohorts of
referred hypertensive patients, followed up at specialized
hypertension centres [3–7,40] or started on antihyper-
tensive treatment at enrolment [4,7,40].
In conclusion, ambulatory monitoring is superior to con-
ventional blood pressure measurement in the prediction
of cardiovascular events. Cardiovascular risk gradually
increases from normotension over white-coat hyperten-
sion and masked hypertension to sustained hypertension.rized reproduction of this article is prohibited.
CDaytime ambulatory versus conventional blood pressure Hansen et al. 1563Risk charts combining ambulatory and conventional
blood pressure measurements along with established
other risk factors are under construction and might
improve risk stratification and the targeted administration
of medical care.
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